P. King

发表

Right ventricular end‐diastolic volume and outcomes in exacerbations of COPD

P. Leong, C. Osadnik, P. King, 2021, Respirology.

Systemic humoral immunity to non‐typeable Haemophilus influenzae

P. King, J. Ngui, D. Gunawardena, 2008, Clinical and experimental immunology.

Phagocyte extracellular traps in children with neutrophilic airway inflammation

P. King, P. Bardin, S. Holdsworth, 2021, ERJ Open Research.

Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry.

G. Maguire, A. Chang, P. Bye, 2019, Respiratory medicine.

Exacerbation phenotyping in chronic obstructive pulmonary disease

P. King, M. MacDonald, K. Hamza, 2013, Respirology.

Cavitary lung disease.

P. King, M. Farmer, P. Cole, 2001, Chest.

Is there a Role for Inhaled Corticosteroids and Macrolide Therapy in Bronchiectasis?

P. King, 2012, Drugs.

Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?

G. Maguire, A. Chang, P. Bye, 2019, Lung.

Characterisation of the onset and presenting clinical features of adult bronchiectasis.

P. King, P. Holmes, S. Holdsworth, 2006, Respiratory medicine.

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation

G. Maguire, A. Chang, M. McDonald, 2010 .

F. Thien, G. Maguire, A. Chang, 2010 .

Bronchiectasis

P. King, P. Holmes, S. Holdsworth, 2006 .

Pharmacotherapy of Chronic Obstructive Pulmonary Disease: Focus on Arformoterol Tartrate

P. King, 2009 .

Microbiologic follow-up study in adult bronchiectasis.

P. King, P. Holmes, S. Holdsworth, 2007, Respiratory medicine.

Role of CFTR mutations in adult bronchiectasis

P. King, P. Holmes, S. Holdsworth, 2004, Thorax.

Prevalence of reduced carbon monoxide transfer factor in smokers with normal spirometry.

P. King, M. MacDonald, P. Bardin, 2021, Respiratory medicine.

Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD.

P. Leong, C. Osadnik, P. King, 2019, Chest.

Outcome in Adult Bronchiectasis

M. Gallagher, P. King, P. Holmes, 2005, COPD.

Haemophilus influenzae and the lung (Haemophilus and the lung)

P. King, 2012, Clinical and Translational Medicine.

Response

P. Leong, C. Osadnik, P. King, 2019, Chest.

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

S. Lewin, J. O’Leary, C. Sobey, 2017, Nature Communications.

Treatable cardiac disease in hospitalised COPD exacerbations

P. Leong, C. Osadnik, P. King, 2021, ERJ Open Research.

Factors associated with "Frequent Exacerbator" phenotype in children with bronchiectasis: The first report on children from the Australian Bronchiectasis Registry.

A. Chang, Gerald Maguire, P. King, 2021, Respiratory medicine.

Severe deficiency of alpha 1-antitrypsin associated with cutaneous vasculitis, rapidly progressive glomerulonephritis, and colitis.

P. King, R. Baynes, J. Kallenbach, 1985, The American journal of medicine.

Nontypeable Haemophilus influenzae Induces Sustained Lung Oxidative Stress and Protease Expression

Daniel P Steinfort, P. King, P. Bardin, 2015, PloS one.

Phenotypes of Adult Bronchiectasis: Onset of Productive Cough in Childhood and Adulthood

P. King, P. Holmes, M. Farmer, 2009, COPD.

Chest pain and exacerbations of bronchiectasis

P. King, P. Holmes, M. Farmer, 2012, International journal of general medicine.

Lung diffusing capacity in adult bronchiectasis: a longitudinal study.

P. King, P. Holmes, M. Farmer, 2010, Respiratory care.

Bronchiectasis and chronic rhinosinusitis

P. King, 2008 .

Raised immunoglobulin E and idiopathic bronchiectasis

P. King, P. Holmes, S. Holdsworth, 2008 .

Cross-talk between IL-6 trans-signaling and AIM2 inflammasome/IL-1β axes bridge innate immunity and epithelial apoptosis to promote emphysema

S. Rose-John, B. Jenkins, P. King, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Management of bronchiectasis

E. Daviskas, P. King, 2010, Breathe.

Reply: To PMID 23142009.

P. King, S. Holdsworth, Steven Lim, 2013, The Journal of allergy and clinical immunology.

Bronchiectasis in indigenous and non‐indigenous residents of Australia and New Zealand

G. Maguire, P. King, Cindy E. Woods, 2018, Respirology.

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines.

G. Maguire, A. Chang, A. Holland, 2015, The Medical journal of Australia.

Effect of interferon gamma and CD40 ligation on intracellular monocyte survival of nontypeable Haemophilus influenzae

P. King, J. Ngui, P. Holmes, 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

A Comparison of Techniques for Optimal Performance of Bronchoalveolar Lavage

Daniel P Steinfort, P. King, M. Farmer, 2015, Journal of bronchology & interventional pulmonology.

Artificial stone-associated silicosis: a rapidly emerging occupational lung disease

D. Yates, P. King, T. Baird, 2017, Occupational and Environmental Medicine.

Visualizing Macrophage Extracellular Traps Using Confocal Microscopy.

P. King, P. Bardin, S. Holdsworth, 2017, Journal of visualized experiments : JoVE.

Churg–Strauss syndrome and bronchiectasis

P. King, 2007 .

The 1918 influenza and COVID‐19 pandemics: The effect of age on outcomes

P. King, S. Londrigan, 2021, Respirology.

Use of antibiotics in bronchiectasis.

P. King, P. Holmes, 2012, Reviews on recent clinical trials.

Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease.

P. King, P. Bardin, J. Ngui, 2013, The Journal of allergy and clinical immunology.

Large Bowel Obstruction Associated with Renal Hypernephroma: A Case Report

P. King, J. Patrick, 1976 .

Adaptive immunity to nontypeable Haemophilus influenzae.

P. Hutchinson, P. King, P. Holmes, 2003, American journal of respiratory and critical care medicine.

NOX2β: A Novel Splice Variant of NOX2 That Regulates NADPH Oxidase Activity in Macrophages

C. Sobey, P. King, G. Drummond, 2012, PloS one.

The Role of the Immune Response in the Pathogenesis of Bronchiectasis

P. King, 2018, BioMed research international.

Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung

G. Brooks, P. King, P. Bardin, 2017, Scientific Reports.

Assessing immune function in adult bronchiectasis

P. Hutchinson, P. King, P. Holmes, 2006, Clinical and experimental immunology.

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

S. Lewin, C. Sobey, P. King, 2017, Nature Communications.

Bacteria in COPD; their potential role and treatment

P. King, M. MacDonald, P. Bardin, 2013, Translational Respiratory Medicine.

Bactericidal activity of neutrophils with reduced oxidative burst from adults with bronchiectasis

P. Hutchinson, P. King, P. Holmes, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The Lung Immune Response to Nontypeable Haemophilus influenzae (Lung Immunity to NTHi)

P. King, Roleen Sharma, 2015, Journal of immunology research.

Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer

P. King, Paul T King, 2015, Clinical and Translational Medicine.

Therapeutic targeting of the IL-6 trans-signalling / mTORC 1 axis in pulmonary emphysema

Sultan, S. Rose-John, Steven, 2018 .

Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema.

S. Rose-John, M. Tate, B. Jenkins, 2016, American journal of respiratory and critical care medicine.

Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung

G. Brooks, P. King, P. Bardin, 2017, Scientific Reports.

Cytotoxic T lymphocyte and natural killer cell responses to non‐typeable Haemophilus influenzae

P. Hutchinson, P. King, J. Ngui, 2008, Clinical and experimental immunology.

Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease.

R. Hancox, P. King, M. MacDonald, 2016, The Lancet. Respiratory medicine.

Role of arformoterol in the management of COPD

P. King, 2008, International journal of chronic obstructive pulmonary disease.

MULTI-PHACET: multidimensional clinical phenotyping of hospitalised acute COPD exacerbations

P. Leong, C. Osadnik, P. King, 2021, ERJ Open Research.

Effect of COVID‐19 lockdown on body weight in chronic obstructive pulmonary disease

K. Polkinghorne, P. King, P. Bardin, 2023, Internal medicine journal.

The pathophysiology of bronchiectasis

P. King, 2009, International journal of chronic obstructive pulmonary disease.

Management of bronchiectasis and chronic suppurative lung disease in Indigenous children and adults from rural and remote Australian communities

G. Maguire, P. Morris, A. Chang, 2008, The Medical journal of Australia.

Pathogenesis of bronchiectasis.

P. King, Paul King, 2011, Paediatric respiratory reviews.

Pathogenesis and diagnosis of bronchiectasis

E. Daviskas, P. King, Paul T. King, 2010, Breathe.

Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand

A. Chang, M. Toombs, A. Holland, 2023, Respirology.

Aspiration and severe exacerbations in COPD: a prospective study

P. Leong, C. Osadnik, P. King, 2020, ERJ Open Research.

C‐reactive protein levels in acute respiratory exacerbations of cystic fibrosis

K. Polkinghorne, P. King, Gayan Kathriachchige, 2018, Internal medicine journal.

The Medical Journal of Australia

G. Maguire, A. Chang, P. King, 2010 .

Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand.

G. Maguire, A. Chang, P. King, 2010, The Medical journal of Australia.

Adaptive immunity to nontypeable Haemophilus influenzae.

P. Hutchinson, P. King, P. Holmes, 2003, American journal of respiratory and critical care medicine.